Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies

Yago Nieto(The University of Texas MD Anderson Cancer Center), Roy B. Jones(The University of Texas MD Anderson Cancer Center), Anna E. Barón(Colorado School of Public Health), Dan Gustafson(University of Colorado Cancer Center), Peter A. McSweeney(Mesoblast (United States)), Steve Matthes(University of Colorado Boulder), Scott I. Bearman(University of Washington), Michael Long(University College Dublin), Pablo J. Cagnoni(University of Colorado Hospital), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center)
Transplantation and Cellular Therapy
April 1, 2005
10.1016/j.bbmt.2005.01.002
Cited by 11

Related Papers

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|PubMed|1996|645